UK markets close in 35 minutes

Medigene AG (0QGJ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
4.2248+0.1388 (+3.40%)
As of 04:23PM BST. Market open.
Full screen
Previous close4.0860
Open4.2248
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range4.2248 - 4.2248
52-week range1.5050 - 4.2248
Volume2,000
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Medigene to Present at Upcoming Conferences

    Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024. 21st CIMT Annual Meeting htt

  • Globe Newswire

    Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor

    Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis antigen, which is expressed in multip

  • Globe Newswire

    Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein

    Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit held in Amsterdam, Netherland